103 related articles for article (PubMed ID: 19123997)
1. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging.
Biffi S; Garrovo C; Macor P; Tripodo C; Zorzet S; Secco E; Tedesco F; Lorusso V
Mol Imaging; 2008; 7(6):272-82. PubMed ID: 19123997
[TBL] [Abstract][Full Text] [Related]
2. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.
Ke S; Wen X; Gurfinkel M; Charnsangavej C; Wallace S; Sevick-Muraca EM; Li C
Cancer Res; 2003 Nov; 63(22):7870-5. PubMed ID: 14633715
[TBL] [Abstract][Full Text] [Related]
3. A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice.
Chen K; Yap LP; Park R; Hui X; Wu K; Fan D; Chen X; Conti PS
Amino Acids; 2012 Apr; 42(4):1329-37. PubMed ID: 21212998
[TBL] [Abstract][Full Text] [Related]
4. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
6. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
7. Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography.
Dullin C; Zientkowska M; Napp J; Missbach-Guentner J; Krell HW; Müller F; Grabbe E; Tietze LF; Alves F
Mol Imaging; 2009; 8(1):2-14. PubMed ID: 19344571
[TBL] [Abstract][Full Text] [Related]
8. In vivo time domain optical imaging of renal ischemia-reperfusion injury: discrimination based on fluorescence lifetime.
Abulrob A; Brunette E; Slinn J; Baumann E; Stanimirovic D
Mol Imaging; 2007; 6(5):304-14. PubMed ID: 18092515
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
10. Oleyl-chitosan nanoparticles based on a dual probe for optical/MR imaging in vivo.
Lee CM; Jang D; Kim J; Cheong SJ; Kim EM; Jeong MH; Kim SH; Kim DW; Lim ST; Sohn MH; Jeong YY; Jeong HJ
Bioconjug Chem; 2011 Feb; 22(2):186-92. PubMed ID: 21243999
[TBL] [Abstract][Full Text] [Related]
11. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
12. [In vivo imaging analysis of biodistribution of FITC-labeled Rituximab in lymphoma-bearing nude mice].
Zhang SH; Cheng X; Zhong GS; Xiong DS; Shao RG
Zhonghua Yi Xue Za Zhi; 2010 Sep; 90(33):2367-70. PubMed ID: 21092502
[TBL] [Abstract][Full Text] [Related]
13. Optical antisense imaging of tumor with fluorescent DNA duplexes.
Liu X; Wang Y; Nakamura K; Liu G; Dou S; Kubo A; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2007; 18(6):1905-11. PubMed ID: 17939728
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
15. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.
Macor P; Tripodo C; Zorzet S; Piovan E; Bossi F; Marzari R; Amadori A; Tedesco F
Cancer Res; 2007 Nov; 67(21):10556-63. PubMed ID: 17975000
[TBL] [Abstract][Full Text] [Related]
16. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
17. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models.
Na JH; Koo H; Lee S; Min KH; Park K; Yoo H; Lee SH; Park JH; Kwon IC; Jeong SY; Kim K
Biomaterials; 2011 Aug; 32(22):5252-61. PubMed ID: 21513975
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
Malviya G; D'Alessandria C; Bonanno E; Vexler V; Massari R; Trotta C; Scopinaro F; Dierckx R; Signore A
J Nucl Med; 2009 Oct; 50(10):1683-91. PubMed ID: 19759100
[TBL] [Abstract][Full Text] [Related]
19. Near-infrared fluorescence imaging of CD13 receptor expression using a novel Cy5.5-labeled dimeric NGR peptide.
Li G; Xing Y; Wang J; Conti PS; Chen K
Amino Acids; 2014 Jun; 46(6):1547-56. PubMed ID: 24652439
[TBL] [Abstract][Full Text] [Related]
20. Near-infrared fluorescence imaging of non-Hodgkin's lymphoma CD20 expression using Cy7-conjugated obinutuzumab.
Lin X; Zhu H; Luo Z; Hong Y; Zhang H; Liu X; Ding H; Tian H; Yang Z
Mol Imaging Biol; 2014 Dec; 16(6):877-87. PubMed ID: 24833041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
